More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
After a conference lacking the wow factor, biotech winners and losers emerge.
ESMO 2024 – iTeos TIGIT meets its efficacy criteria
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
